Phase 1 Lung Cancer Trial, Recruiting NCT06228482 Sponsor: University of California, Davis Condition: Lung Cancer
Back to Lung Cancer

Phase 1 Lung Cancer Trial, Recruiting

NCT06228482
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older who are willing and able to sign a written consent form
  • People who have been diagnosed with non-small cell lung cancer (NSCLC) that has spread to other parts of the body, with at least one tumour large enough to be measured on scans
  • People whose cancer has continued to grow or spread during or after at least one previously approved drug treatment
  • People who have stored tumour tissue samples available from a previous biopsy or surgery
  • People who are reasonably active and able to carry out basic daily activities (a doctor will assess this using a standard scale)
  • People who have finished their last cancer treatment at least 2 weeks before the initial scan, and whose side effects from that treatment have mostly cleared up
  • People whose blood counts are within acceptable ranges, including white blood cells, platelets, and haemoglobin (confirm with trial site)
  • People whose liver and kidney function blood test results are within acceptable ranges
  • People with a life expectancy of at least 3 months
  • People who are able to lie still without moving for 30 to 60 minutes during a scan
  • For the treatment part of the trial: people who have completed the initial scan and whose scan shows the cancer is visible using the special imaging agent used in this trial

Who may not be able to join:

  • People with severe heart failure (classified as Class 3 or 4 on a standard medical scale)
  • People who have had significant bleeding, such as from the stomach, intestines, or brain, within the two weeks before joining the trial
  • People who are pregnant or breastfeeding
  • People who have had major surgery involving general anaesthesia within 28 days before the trial starts, or who are expected to need such surgery within 6 weeks of starting
  • People who have another active cancer that has required treatment within the past 2 years (certain early-stage, treated skin cancers and some non-invasive cancers may be exceptions — confirm with trial site)
  • People with an active bacterial, viral, or fungal infection that has not been controlled despite treatment
  • People with mental health or personal circumstances that would make it difficult to follow the trial requirements
  • People who weigh more than 350 pounds (approximately 159 kg), as the scanning equipment has a weight limit
  • People with known scarring or inflammation of the lung tissue (interstitial lung disease or pulmonary fibrosis)
  • People with blood clotting test results outside the acceptable range (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Julie L Sutcliffe, PhD, University of California, Davis

Phone: 9167345536

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
22 January 2024
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

[68Ga]Ga DOTA-5G PET/CT imaging; [177Lu]Lu DOTA-ABM-5G treatment; [177Lu]Lu DOTA-ABM-5G treatment efficacy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov